Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)

NCT03018340 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

207

Enrollment

INDUSTRY

Sponsor class

Conditions

Adjunctive Treatment of Major Depressive Disorder

Interventions

DRUG: Pimavanserin
OTHER: Placebo

Sponsor

ACADIA Pharmaceuticals Inc.